Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial

BACKGROUND: Lung nodules are a diagnostic challenge, with an estimated yearly incidence of 1.6 million in the United States. This study evaluated the accuracy of an integrated proteomic classifier in identifying benign nodules in patients with a pretest probability of cancer (pCA) ≤ 50%. METHODS: A...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Chest
Main Authors: Silvestri, Gerard A., Tanner, Nichole T., Kearney, Paul, Vachani, Anil, Massion, Pierre P., Porter, Alexander, Springmeyer, Steven C., Fang, Kenneth C., Midthun, David, Mazzone, Peter J.
Formato: Artigo
Idioma:Inglês
Publicado em: American College of Chest Physicians 2018
Assuntos:
Lung Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6689113/
https://ncbi.nlm.nih.gov/pubmed/29496499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.chest.2018.02.012
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados